Endothelial Glycocalyx Degradation as a Central Mechanism in Premature Atherosclerotic Cardiovascular Disease
DOI:
https://doi.org/10.37034/medinftech.v4i3.143Keywords:
Atherosclerotic Cardiovascular Disease, Endothelial Glycocalyx, Endothelial Dysfunction, Microvascular Dysfunction, Oxidative StressAbstract
Premature atherosclerotic cardiovascular disease (ASCVD) poses a substantial clinical burden. Endothelial glycocalyx injury has been proposed as a contributor to vascular dysfunction and atherosclerotic processes, but its role in premature ASCVD remains uncertain. This narrative review examines evidence on glycocalyx structure and degradation, associated vascular mechanisms, candidate biomarkers, and potential therapeutic approaches. Literature published from 2010 to March 2026 was identified through PubMed, Scopus, Web of Science, and Google Scholar using terms related to the endothelial glycocalyx, atherosclerosis, endothelial dysfunction, and cardiovascular disease. Earlier foundational studies were also considered. Experimental and clinical literature links glycocalyx injury with altered vascular permeability, mechanotransduction, nitric oxide signaling, and inflammatory cell interactions. Oxidative stress, hyperglycemia, inflammation, and disturbed flow have been investigated as potential contributors to glycocalyx damage. Circulating glycocalyx components, including syndecan-1, are being studied as markers of endothelial injury, but their value for predicting premature ASCVD has not been established. Although glycocalyx preservation and restoration are potential therapeutic research directions, evidence that these approaches prevent premature cardiovascular events is lacking. Overall, glycocalyx injury is a biologically plausible contributor to atherosclerotic processes; prospective human studies are needed to establish its causal and predictive roles in premature ASCVD.
Downloads
References
A. Milusev, R. Rieben, and N. Sorvillo, “The Endothelial Glycocalyx: A Possible Therapeutic Target in Cardiovascular Disorders,” Front. Cardiovasc. Med., vol. Volume 9-, 2022, doi: 10.3389/fcvm.2022.897087.
P. Libby et al., Braunwald’s Heart Disease - E-Book: A Textbook of Cardiovascular Medicine. Elsevier, 2021. [Online]. Available: https://books.google.co.id/books?id=rXZIEAAAQBAJ
L. S. Lilly, Pathophysiology of Heart Disease: An Introduction to Cardiovascular Medicine, 7e. Lippincott Williams & Wilkins, a Wolters Kluwer business, 2021.
A. Gomez Toledo, G. J. Golden, R. D. Cummings, J. Malmström, and J. D. Esko, “Endothelial Glycocalyx Turnover in Vascular Health and Disease: Rethinking Endothelial Dysfunction,” Annu. Rev. Biochem., vol. 94, no. Volume 94, 2025, pp. 561–586, 2025, doi: https://doi.org/10.1146/annurev-biochem-032620-104745.
B. M. van den Berg, H. Vink, and J. A. E. Spaan, “The Endothelial Glycocalyx Protects Against Myocardial Edema,” Circ. Res., vol. 92, no. 6, pp. 592–594, 2003, doi: 10.1161/01.RES.0000065917.53950.75.
H. Vink and B. R. Duling, “Identification of Distinct Luminal Domains for Macromolecules, Erythrocytes, and Leukocytes Within Mammalian Capillaries,” Circ. Res., vol. 79, no. 3, pp. 581–589, Sep. 1996, doi: 10.1161/01.RES.79.3.581.
K. H. Moore, H. A. Murphy, and E. M. George, “The glycocalyx: a central regulator of vascular function.,” Am. J. Physiol. Regul. Integr. Comp. Physiol., vol. 320, no. 4, pp. R508–R518, Apr. 2021, doi: 10.1152/ajpregu.00340.2020.
O. Yilmaz, B. Afsar, A. Ortiz, and M. Kanbay, “The role of endothelial glycocalyx in health and disease.,” Clin. Kidney J., vol. 12, no. 5, pp. 611–619, Oct. 2019, doi: 10.1093/ckj/sfz042.
M. A. J. Gimbrone and G. García-Cardeña, “Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis.,” Circ. Res., vol. 118, no. 4, pp. 620–636, Feb. 2016, doi: 10.1161/CIRCRESAHA.115.306301.
P. Libby, “The changing landscape of atherosclerosis.,” Nature, vol. 592, no. 7855, pp. 524–533, Apr. 2021, doi: 10.1038/s41586-021-03392-8.
S. Godo and H. Shimokawa, “Endothelial Functions,” Arterioscler. Thromb. Vasc. Biol., vol. 37, no. 9, pp. e108–e114, 2017, doi: 10.1161/ATVBAHA.117.309813.
A. Krüger-Genge, A. Blocki, R.-P. Franke, and F. Jung, “Vascular Endothelial Cell Biology: An Update,” Int. J. Mol. Sci., vol. 20, no. 18, 2019, doi: 10.3390/ijms20184411.
S. Reitsma, D. W. Slaaf, H. Vink, M. A. M. J. van Zandvoort, and M. G. A. oude Egbrink, “The endothelial glycocalyx: composition, functions, and visualization.,” Pflugers Arch., vol. 454, no. 3, pp. 345–359, Jun. 2007, doi: 10.1007/s00424-007-0212-8.
J. M. Tarbell and E. E. Ebong, “The endothelial glycocalyx: a mechano-sensor and -transducer.,” Sci. Signal., vol. 1, no. 40, p. pt8, Oct. 2008, doi: 10.1126/scisignal.140pt8.
M. Nieuwdorp et al., “Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo.,” Diabetes, vol. 55, no. 2, pp. 480–486, Feb. 2006, doi: 10.2337/diabetes.55.02.06.db05-1103.
N. Marx et al., “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.,” Eur. Heart J., vol. 44, no. 39, pp. 4043–4140, Oct. 2023, doi: 10.1093/eurheartj/ehad192.
P. Ong et al., “International standardization of diagnostic criteria for microvascular angina,” Int. J. Cardiol., vol. 250, pp. 16–20, Jan. 2018, doi: 10.1016/j.ijcard.2017.08.068.
F. L. J. Visseren et al., “2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.,” Eur. Heart J., vol. 42, no. 34, pp. 3227–3337, Sep. 2021, doi: 10.1093/eurheartj/ehab484.
P. I. Johansson, J. Stensballe, L. S. Rasmussen, and S. R. Ostrowski, “A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients.,” Ann. Surg., vol. 254, no. 2, pp. 194–200, Aug. 2011, doi: 10.1097/SLA.0b013e318226113d.
J. G. Murphy and issuing body. Mayo Foundation for Medical Education and Research, Mayo Clinic cardiology : concise textbook , Fifth edit. in Mayo Clinic scientific press. New York, NY: Oxford University Press, 2024.
Z. I. Attia et al., “An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction,” Lancet, vol. 394, no. 10201, pp. 861–867, Sep. 2019, doi: 10.1016/S0140-6736(19)31721-0.
Z. I. Attia et al., “Screening for cardiac contractile dysfunction using an artificial intelligence–enabled electrocardiogram,” Nat. Med., vol. 25, no. 1, pp. 70–74, 2019, doi: 10.1038/s41591-018-0240-2.
W.-H. Weng et al., “Predicting cardiovascular disease risk using photoplethysmography and deep learning,” PLOS Glob. Public Heal., vol. 4, no. 6, pp. 1–20, 2024, doi: 10.1371/journal.pgph.0003204.
